Editorials

All That Glitters Is Not Gold — Standardizing Diagnosis in Rheumatoid Arthritis Studies
K.P. Liao, V. Bykerk .................................. 1223

Who’s Holding up the Queue? Delay in Treatment of Rheumatoid Arthritis
J.E. Homik .............................................. 1225

Rehabilitation for Ankylosing Spondylitis in the Era of Biologics: Any Room Left for This Treatment? E. Lubrano, S. D’Angelo, A. Spadaro, C. Palazzi, I. Olivieri .................................. 1228

Should Clinicians Start Measuring Flow Mediated Dilation Response in Patients with Systemic Lupus Erythematosus? C.S. Lau .......................................................... 1231

Review

Challenges in Diagnosing Latent TB Infection in Patients Treated with TNF Antagonists
E.C. Keystone, K.A. Papp, W. Wobeser .................................. 1234

Articles


Diagnostic Accuracy of ACR/EULAR 2010 Criteria for RA in a 2-Year Cohort S. Varache, D. Cornec, J. Morvan, et al .................................. 1250


A Comparison Between IgG- and IgA-class Antibodies to CCP and to Modified Citrullinated Vimentin in Early RA and Very Early Arthritis A. Svärd, A. Kastbom, M.K. Söderlin, A. Reckner-Olsson, T. Skogh .............................................. 1265

Persistence with Anti-TNF Therapies in Patients with RA: Observations from the RADIUS Registry J.A. Markenson, A. Gibofsky, W.R. Palmer, et al .................................. 1273

Time to Treatment for New Patients with RA in a Major Metropolitan City S. Jamal, S.M.H. Alibhai, E.M. Badley, C. Bombardier .................................................. 1282

Prognostic Indicators of Hospitalized Patients with SLE: A Large Retrospective Multicenter Study in China X. Feng, Y. Zou, W. Pan, et al ................................ 1289

Endothelium-dependent But Not Endothelium-independent Flow-mediated Dilation Is Significantly Reduced in Patients with SLE without Vascular Events: A Metaanalysis and Metaregression A. Mak, Y. Liu, R.C-M Ho ...................................................... 1296

Longterm Followup After Tapering MMF During Maintenance Treatment for Proliferative Lupus Nephritis K. Laskari, A.G. Tzioufas, A. Antoniou, H.M. Moutsopoulos .................................. 1304

Quantitative Data for Care of Patients with SLE in Usual Clinical Settings: A Patient Multidimensional HAQ and Physician Estimate of Noninflammatory Symptoms A.D. Askarane, I. Castrejón, T. Pincus ........................................ 1309

Late-age Onset SSC R.L. Manno, F.M. Wigley, A.C. Gelber, L.K. Hummers .......................... 1317

Expert Agreement on EULAR/EUSTAR Recommendations for the Management of SSc K.M. Walker, J. Pope, on behalf of the Scleroderma Clinical Trials Consortium and the Canadian Scleroderma Research Group .................................. 1326


Rehabilitation Treatment in Patients with AS Stabilized with TNF Inhibitor Therapy, A Randomized Controlled Trial S. Masiero, L. Bonaldo, M. Pigatto, A. Lo Nigro, R. Ramonda, L. Punzi ........................................ 1335


Candidate Genes in Patients with Autoinflammatory Syndrome Resembling TNF Receptor-associated Periodic Syndrome Without Mutations in the TNFRSF1A Gene S. Borghini, M. Fiore, M. Di Duca, et al .................................. 1378
Pediatric Rheumatology

Heterotopic Ossification of the TMJ in JIA
S. Ringold, M. Thapa, E.A. Shaw, C.A. Wallace  1423

MBL Expression Genotype in Pediatric-onset SLE: Associations with Susceptibility to Renal Disease and Protection Against Infections Y-C. Tsai, K-W. Yeh, T-C. Yao, Y-L. Huang, M-L. Kuo, J-L. Huang  1429

Safety and Efficacy of Rituximab in Severe Juvenile DM: Results from 9 Patients from the French Autoimmunity and Rituximab Registry B. Bader-Meunier, H. Decaluwe, C. Barnerias, et al. for the Club Rhumatismes et Inflammation  1436

Development of IBD in Patients with JIA Treated with Etanercept T.D. van Dijken, S.J. Vastert, V.M. Gerloni, et al.  1441

Images in Rheumatology

Fluorescence Optical Imaging of Juvenile Arthritis
S.G. Werner, H-E. Langer, G. Horneff  1447

OMERACT 10

10th International Consensus Conference on Outcome Measures in Rheumatology Kota Kinabalu, Borneo - May 4-8, 2010
Introduction  1448

Disease-specific Outcomes


Tophus Measurement as an Outcome Measure for Clinical Trials of Chronic Gout: Progress and Research Priorities N. Dalbeth, F.M. McQueen, J.A. Singh, et al.  1458

Serum Urate in Chronic Gout — Will It Be the First Validated Soluble Biomarker in Rheumatology? L.K. Stamp, P.P. Khanna, N. Dalbeth, et al.  1462


Development of Outcome Measures for Large-vessel Vasculitis for Use in Clinical Trials: Opportunities, Challenges, and Research Agenda H. Direshkeneli, S.Z. Aydin, T.A. Kermani, et al.  1471

The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis P.A. Merkel, S.Z. Aydin, M. Boers, et al.  1480

Toward Development of a FM Responder Index and Disease Activity Score: OMERACT Module Update P.J. Mease, D.J. Clauw, R. Christensen, et al. and the OMERACT Fibromyalgia Working Group  1487

Development of a Disease Severity and Responder Index for PsA — Report of the OMERACT 10 PsA SIG L.C. Coates, A. Mumentz, P.S. Helliwell, et al.  1496

Endorsement of Definitions of Disease Activity States and Improvement Scores for the AS Disease Activity Score: Results from OMERACT 10 P.M.M.C. Machado, R.B.M. Landewé, D.M. van der Heijde  1502


Developing Disease Activity and Response Criteria in CTD-related ILD L.A. Saketkoo, E.L. Matteson, K.K. Brown, J.R. Seibold, V. Strand; for the Connective Tissue Disease-related Interstitial Lung Disease Special Interest Group.  1514

Correspondence

Where in the World is Oral Triamcinolone? L. Roger  1519

Reply R. Aiten.  1519

Lupus Related Longitudinal Myelitis D.M. Wingerchuk, B.G. Weisman  1520

Reply P. Zotos  1521


Who Discovered the ESR? A. Grzybowski, J.J. Sak  1521

Reply E.L. Matteson, C.S. Crowson.  1523

Letters


Acute Presentation of Tophaceous Myelopathy E. Levin, K. Hurth, R. Joshi, R. Brasington  1525

AS Refractory to TNF Blockade Responds to Tocilizumab J-D. Cohen, R. Ferreira, C. Jorgensen  1527

Positive C-ANCA with PR3 Specificity Glomerulonephritis in a Patient with Subacute Bacterial Endocarditis M. Uh, I.A. McCormick, J.T. Kelsall  1528

Primary Aldosteronism Simulating Polymyositis Y-C. Tang, S-K. Wang, W-L. Yuan  1529

Corrections

Intraarticular Botulinum Toxin A for Refractory Painful Total Knee Arthroplasty: A Randomized Controlled Trial J.A. Singh, M.L. Mahowald, S. Noorbaloocchi.  1534


Meetings in Rheumatology

...